SeekingAlpha · Jun 23, 2026
InfuSystem: A Good Time To Buy Before A Potential Breakout
InfuSystem (INFU) stock: buy case on 11.6% FCF yield, margin gains, low EV/EBITDA, and ERP efficienciesâplus key risks. See more details here.
AMEX · INFU
Healthcare · Medical - Instruments & Supplies
$12.21
Up+$0.01 (+0.08%)
Updated Aug 23, 2026, 4:11 PM
SID Score
6.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
INFU closed at $12.21 after 20 trading sessions, up 30.45% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $12.25 | $12.34 | $12.0001 | $12.21 | 99.98K |
| Aug 20, 2026 | $12.20 | $12.38 | $12.10 | $12.20 | 107.23K |
| Aug 19, 2026 | $12.30 | $12.50 | $12.09 | $12.19 | 107.72K |
| Aug 18, 2026 | $12.20 | $12.35 | $12.01 | $12.23 | 80.57K |
| Aug 17, 2026 | $12.13 | $12.19 | $11.90 | $12.16 | 94.77K |
| Aug 14, 2026 | $12.42 | $12.54 | $12.09 | $12.27 | 74.81K |
| Aug 13, 2026 | $12.31 | $12.54 | $12.22 | $12.48 | 116.75K |
| Aug 12, 2026 | $12.40 | $12.40 | $12.025 | $12.24 | 116.42K |
| Aug 11, 2026 | $12.14 | $12.52 | $12.03 | $12.46 | 144.66K |
| Aug 10, 2026 | $12.42 | $12.5286 | $12.04 | $12.12 | 200.54K |
| Aug 7, 2026 | $11.82 | $12.49 | $11.5884 | $12.49 | 199.53K |
| Aug 6, 2026 | $12.10 | $12.10 | $11.58 | $11.87 | 182.5K |
| Aug 5, 2026 | $12.07 | $12.97 | $11.99 | $12.15 | 443.88K |
| Aug 4, 2026 | $10.14 | $12.50 | $9.875 | $12.32 | 582.07K |
| Aug 3, 2026 | $9.22 | $9.525 | $9.11 | $9.22 | 238.25K |
| Jul 31, 2026 | $9.18 | $9.44 | $8.88 | $9.14 | 172.81K |
| Jul 30, 2026 | $9.69 | $9.76 | $9.14 | $9.19 | 150.91K |
| Jul 29, 2026 | $9.81 | $10.00 | $9.4214 | $9.76 | 173.24K |
| Jul 28, 2026 | $9.43 | $9.94 | $9.3553 | $9.92 | 114.17K |
| Jul 27, 2026 | $9.12 | $9.52 | $9.12 | $9.36 | 128.95K |
The latest Smart Investors Daily articles mentioning INFU.
INFU research
Company profile and research snapshot.
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-reportable segment. The first is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second, Device Solutions, supports the Patient Services platform and leverages service orientation to win incremental business from its direct payer clients. The Device segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair. Majority from Patient.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 5, 2026 | B. Riley Securities | Buy | — |
| Feb 25, 2026 | Roth Capital | Buy | — |
| Nov 5, 2025 | Roth Capital | Buy | — |
| Jul 22, 2025 | Roth Capital | Buy | — |
| Sep 26, 2024 | B. Riley Securities | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Jun 23, 2026
InfuSystem (INFU) stock: buy case on 11.6% FCF yield, margin gains, low EV/EBITDA, and ERP efficienciesâplus key risks. See more details here.
Benzinga · Feb 25, 2026
Roth Capital analyst Kyle Bauser reiterates InfuSystems Holdings (AMEX:INFU) with a Buy and raises the price target from $14 to $15.
ChartMill · Feb 24, 2026
InfuSystem reports strong 2025 earnings and margin growth, despite a slight revenue miss. The company restructured a key contract to boost future profitability.
SeekingAlpha · Feb 24, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning INFU.